Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

33.09
-0.5400-1.61%
Volume:577.55K
Turnover:19.22M
Market Cap:1.97B
PE:-4.72
High:34.09
Open:33.62
Low:32.95
Close:33.63
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.51
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.92
PE(LYR):-4.65

Loading ...

BRIEF-Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic Syndromes

Reuters
·
May 29

BUZZ-U.S. STOCKS ON THE MOVE-Costco, Firefly Aerospace, Agios

Reuters
·
May 29

Agios Pharma Won't Advance Tebapivat for Lower-Risk Myelodysplastic Syndromes

Dow Jones
·
May 29

Agios Halts Development of Tebapivat in Lower-Risk MDS After Mid-Stage Trial Miss; Shares Drop Premarket

MT Newswires Live
·
May 29

Agios will not advance tebapivat in lower-risk myelodysplastic syndromes

TIPRANKS
·
May 29

Agios Pharmaceuticals Shares Fall 19% Premarket After Co to Stop Development of Its Blood Disorder Drug

THOMSON REUTERS
·
May 29

Agios scraps blood disorder drug program after study miss

Reuters
·
May 29

Agios Pharmaceuticals - Tebapivat Phase 2 Trial in Sickle Cell Disease Topline Data Expected Second Half 2026

THOMSON REUTERS
·
May 29

Agios Pharmaceuticals - Phase 2B Trial Results for Tebapivat in Lr-Mds Did Not Meet Predefined Threshold

THOMSON REUTERS
·
May 29

Agios Pharmaceuticals - Tebapivat Well Tolerated With No New Safety Signals Identified

THOMSON REUTERS
·
May 29

Agios Pharmaceuticals - Will Not Advance Tebapivat in Lower-Risk Myelodysplastic Syndromes

THOMSON REUTERS
·
May 29

Analysts Offer Insights on Healthcare Companies: Clinuvel Pharmaceuticals (OtherCLVLF) and Agios Pharma (AGIO)

TIPRANKS
·
May 25

Will EU Thalassemia Approval for PYRUKYND Redefine Agios Pharmaceuticals' (AGIO) Mitapivat-Centric Investment Narrative?

Simply Wall St.
·
May 25

Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)

TIPRANKS
·
May 23

BRIEF-Avanzanite Bioscience’S Partner Agios Announces Pyrukynd® (Mitapivat) Approval In EU

Reuters
·
May 22

Agios Gets EU Approval for Pyrukynd in Thalassemia

MT Newswires Live
·
May 22

Agios says EU approves PYRUKYND for adults with alpha- or beta-thalassemia anemia

Reuters
·
May 22

Agios’ Pyrukynd® (Mitapivat) Approved in the European Union for Adults With Thalassemia

THOMSON REUTERS
·
May 22

Analysts Are Bullish on These Healthcare Stocks: Actuate Therapeutics, Inc. (ACTU), Agios Pharma (AGIO)

TIPRANKS
·
May 13

Agios Pharmaceuticals to present mitapivat data at EHA Congress

TIPRANKS
·
May 13